Best Infectious Diseases Companies in Boston, United States
The 37 best Infectious Diseases companies in Boston, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Atea.
Our analysis of 50 Infectious Diseases companies
$7.1b in tracked funding; 59% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Infectious Diseases companies in Boston
| # | Company | Disclosed funding | Last round | Employees | Founder | Stage | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Atea Developer of therapeutics for viral diseases | $293M | 39 mo ago | 58 58 → 58 (+0%) | Jean Sommadossi Founder & CEO | Public | — | — |
| 2 | binx health Developer of a diagnostic platform for sexually transmitted infections | $284M | 29 mo ago | 46 46 → 93 (+102%) | — | Series F | — | — |
| 3 | RVAC Medicines Developer of therapeutics to treat infectious and other diseases | $140M | 52 mo ago | 56 | — | Deadpooled | 6 patents mRNA therapeutic manufacturing, engineered UTRs, and lipid nanoparticle delivery platforms | — |
| 4 | Acetylon Global biopharmaceutical company discovering, developing, and delivering innovative medicines | $138M | 157 mo ago | 37 | Marc Cohen Co-Founder | Acqui-Hired | — | — |
| 5 | HilleVax Developer of a vaccine for norovirus infection | $135M | 60 mo ago | 62 | — | Public | — | — |
| 6 | Paratek Pharma Developer of therapeutics for antimicrobial resistant infections | $96M | 59 mo ago | 205 205 → 446 (+118%) | — | Acquired | — | — |
| 7 | Daktari Diagnostics Point of care diagnostic platform and data management system | $73M | 112 mo ago | 23 | — | Series D | 44 patents Particle counting and microfluidic fluid analysis for diagnostic and analytical applications | — |
| 8 | Day Zero Diagnostics Developer of genome sequencing-based diagnostics for infectious diseases | $49M | 35 mo ago | 52 | Jong Lee CEO & Cofounder | Series B | — | — |
| 9 | Arietis Developing novel antibiotics to combat drug-resistant bacterial pathogens and infections | $41M | 17 mo ago | 5 | Kim Lewis Founder | Funding Raised | 2 patents Antibacterial compounds targeting dormant/non-replicating bacterial cells | — |
| 10 | Aldatu Biosciences Innovative PCR diagnostics for infectious diseases, advancing global health emergency response | $18M | 48 mo ago | 11 | — | Funding Raised | — | — |
| 11 | NanoView Biosciences Provider of a nanotechnology based molecular diagnostic platform | $16M | 54 mo ago | 24 | — | Acqui-Hired | — | — |
| 12 | FLUID Provider of microfluidic technology for microbial profiling and diagnostics | $10M | 61 mo ago | 5 | Monika Weber Founder & CEO | Series A | — | — |
| 13 | PhagePro Developing phage treatments to combat antibiotic resistance and promote health equity | $5M | 21 mo ago | 5 | Minmin Yen Co-Founder & CEO | Funding Raised | — | — |
| 14 | Oxbridge Clinical Home | Oxbridge Clinical | $4M | 11 mo ago | — | Cristiano Peron Co-Founder and Chief Medical Officer | Series A | 4 patents Microbial detection and quantification using biosensor-based identification apparatus | 1 job opening |
| 15 | InnoTech Precision Medicine Developer of multimodal molecular diagnostic platform for early disease detection | $3M | 13 mo ago | 5 | Reza Mollaaghababa Co-Founder | Funding Raised | — | — |
| 16 | Porosome Developer of therapeutics for secretory and hydration disorders | $1M | 36 mo ago | — | Octavian Bucur Co-Founder | Seed | — | — |
| 17 | Propedix Developer of therapeutics for fungal diseases | $800K | 22 mo ago | — | Carl Schanbacher Founder | Seed | — | — |
| 18 | VaxSyna Developer of vaccine and antibody therapeutics | $437K | 53 mo ago | 4 | Joseph Hunter Co-Chief Executive Officer | Funding Raised | — | — |
| 19 | Quarksen Developer of a sensing device for diagnosing multiple diseases | $275K | 26 mo ago | — | Zohreh Izadifar Co-Founder | Funding Raised | — | — |
Top 12 Infectious Diseases companies in Boston
#1
Funding Raised · Boston, Massachusetts · founded 2008 · 5 employees$41.4Mraised▾
Developing novel antibiotics to combat drug-resistant bacterial pathogens and infections. This biotech company is focused on creating first-in-class small molecule antibiotics to address the high unmet clinical need in treating infections caused by drug-resistant bacteria. Their innovative approach involves activating the ClpP protease, causing bacterial cells to self-digest, offering a unique mechanism to overcome resistance. This strategy is particularly effective against ESKAPE pathogens and Streptococcus pneumoniae, even targeting non-growing cells and biofilms, which are often resistant to traditional antibiotics. By combining ClpP activators with existing antibiotics, they aim to prevent resistance development and eradicate infections more effectively, potentially revolutionizing the treatment of complicated infections and reducing recurrence. Their research and development efforts are geared towards addressing the critical threat of antimicrobial resistance, especially in Gram-positive pathogens, and providing novel solutions for infections like endocarditis, osteomyelitis, and diabetic ulcers.
- Apr 2025Grant (prize money)$6.4M
- Sep 2023Grant (prize money)$2M
- Mar 2021Grant (prize money)$3M
- Dec 2018Grant (prize money)$6.4M
#2
Series A · Boston, Massachusetts · founded 2023$4.5Mraised▾
Home | Oxbridge Clinical
- Oct 2025Series A$4.5M
#3
Funding Raised · Boston, Massachusetts · founded 2021 · 5 employees$2.9Mraised▾
Developer of multimodal molecular diagnostic platform for early disease detection. It focuses on creating diagnostic solutions, particularly for cancer, by integrating molecular biology and engineering. The company's platform aims to provide accurate and accessible diagnostics to empower patients and healthcare providers. It develops and commercializes a diagnostic platform that utilizes multimodal detection to identify disease biomarkers. The company collaborates with scientists, engineers, and clinicians to ensure its diagnostic platform meets patient care standards.
- Aug 2025Grant (prize money)$329.7K
- Apr 2025Grant (prize money)$756K
- Jan 2025Grant (prize money)$756K
- Sep 2023Grant (prize money)$329.7K
#4
Series F · Boston, Massachusetts · founded 2005 · 46 employees$284.3Mraised▾
Developer of a diagnostic platform for sexually transmitted infections. The platform, io Diagnostic System is a PCR-based, portable, and point-of-care testing platform for sexually transmitted infections (STIs). The company is developing this platform for both clinical and at-home applications. The company also developing other products such as io MSTI Cartridge for detection of Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis.
- Apr 2024Series F$65M
- May 2021Series E$104M
- Aug 2017Grant (prize money)$2.6M
- Jan 2017Series D$35M
#5
Funding Raised · Boston, Massachusetts · founded 2016 · 5 employees$5.2Mraised▾
Developing phage treatments to combat antibiotic resistance and promote health equity. This organization is dedicated to developing phage treatments for global health disparities and antibiotic resistance. They harness the power of phages, natural hunters of bacteria, to tackle prolific diseases as an alternative to antibiotics. The company brings together experts in public policy, industry, and commercialization with community leaders to drive innovation in underserved communities. Their lead program focuses on Cholera, reflecting their commitment to addressing critical health challenges. This is a biotech company focused on social impact, offering innovative solutions to combat antibiotic resistance and promote health equity through phage therapy.
- Dec 2024Grant (prize money)$1M
- Jul 2024Grant (prize money)$173.3K
- Jan 2021Grant (prize money)$383.2K
- Dec 2018Grant (prize money)$3.6M
#6
Public · Boston, Massachusetts · founded 2014 · 58 employees$293.4Mraised▾
Developer of therapeutics for viral diseases. It helps users in the treatment of infections caused by RNA and DNA viruses. It also gives solutions for various diseases like Hepatitis C, Dengue, Respiratory Syncytial Virus (RSV), Hepatitis B, and many more.
- Jun 2023Post IPO—
- May 2020Series D$215M
- Jul 2018Series C$27.6M
- Sep 2016Series A$20.8M
#7
Series B · Boston, Massachusetts · founded 2016 · 52 employees$49Mraised▾
Developer of genome sequencing-based diagnostics for infectious diseases. The company offers diagnostic solutions based on machine learning and genomics for infectious diseases. The assay includes Blood2Bac and BacDetect that uses whole-genome sequencing to identify both infecting species and drug resistance in bacterial infections.
- Sep 2023Series B$16M
- Aug 2023Grant (prize money)$300K
- Oct 2022Grant (prize money)$8.2M
- Feb 2022Series B$21M
#8
Seed · Boston, Massachusetts · founded 2024$800Kraised▾
Developer of therapeutics for fungal diseases. It offers topical treatments based on anti-fungal and drying agent technology for the treatment of Athletes foot and other fungal disease.
- Nov 2024Seed$800K
#9
Deadpooled · Boston, Massachusetts · founded 2021 · 56 employees$140Mraised▾
Developer of therapeutics to treat infectious and other diseases. The company leverages mRNA, vaccines, and lipid nanoparticle (LNP) technologies to develop a pipeline of products against COVID-19 and SARS-CoV2 variants, as well as innovative treatments against other infectious diseases.
- Apr 2022Series B$140M
#10
Acquired · Boston, Massachusetts · founded 1996 · 205 employees$96.5Mraised▾
Developer of therapeutics for antimicrobial resistant infections. The company's lead candidate is NUZYRA(omadacycline), an oral and intravenous antibiotic for the treatment of adults with Community-Acquired Bacterial Pneumonia (CABP) and Acute Bacterial Skin and Skin Structure Infection (ABSSSI) caused by select susceptible microorganisms. Other drugs include Seysara for the treatment of inflammatory lesions of non-modular moderate to severe acne vulgaris.
- Sep 2021Grant (prize money)—
- Apr 2018Post IPO$160M
- Jun 2016Post IPO$59.7M
- May 2015Post IPO$71.1M
#11
Public · Boston, Massachusetts · founded 2021 · 62 employees$135Mraised▾
Developer of a vaccine for norovirus infection. The lead candidate HIL-214 is a norovirus bivalent GI.1/GII.4 virus-like particle vaccine indicated for active immunization for the prevention of acute gastroenteritis caused by norovirus.
- Sep 2021Series D$135M
#12
Funding Raised · Boston, Massachusetts · founded 2014 · 11 employees$17.8Mraised▾
Innovative PCR diagnostics for infectious diseases, advancing global health emergency response. The company is a public benefit corporation focused on advancing infectious disease diagnostics to facilitate society's response to global health emergencies. They have established the Pan Degenerate Amplification and Adaptation (PANDAA™) platform to enable target detection in highly variable genomic regions with RT-PCR. Their proprietary PANDAA technology allows the development of fast, reliable, and cost-effective diagnostic tests for infectious diseases. The company's pipeline includes products for the detection of SARS-CoV-2, Lassa virus, and drug-resistant HIV variants. The high-throughput, low-cost PANDAA platform improves patient healthcare access and outcomes. They offer products and services related to HIV drug resistance, pandemic preparedness for VHFs (Lassa fever, Crimean-Congo hemorrhagic fever, Ebola and Marburg, Yellow fever virus), and SARS-CoV-2 detection and variant genotyping. They also provide enzymes and hot start RT products. Their adaptive PCR using PANDAA technology ensures the enduring integrity of molecular diagnostics as assay redesign is not required to detect
- Sep 2022Grant (prize money)$3M
- Aug 2022Grant (prize money)$2.8M
- Mar 2021Grant (prize money)$2.7M
- Apr 2019Grant (prize money)$299.7K
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Infectious Diseases coverage by sub-theme.
Regulatory-risk over time falling
Funding & growth over time
funding flat · growth falling
How research on Diagnostics in Boston is moving
A read on the academic research around Diagnostics in Boston — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 164 papers.
- Boston University67
- Boston Children\'s Hospital62
- Boston Medical Center17
- Dana-Farber/Boston Children\'s Cancer and Blood Disorders Center12
- Boston College5
- Point-of-care testing11
- Point of care9
- Liquid biopsy6
- Biomarker5
- Microfluidics5
- Liquid biopsy2→8
- Internal medicine2→6
- Point-of-care testing9→12
- Diagnostic test2→3
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.